Bronchodilator Drugs - France

France

The projected revenue in the Bronchodilator Drugs market in France is expected to reach €0.70bn in 2024.
It is anticipated that the revenue will show an annual growth rate (CAGR 2024-2029) of 3.47%, leading to a market volume of €0.83bn by 2029.
In comparison to other countries, United States is projected to generate the highest revenue in the market, amounting to €16,080.00m in 2024.
France's pharmaceutical market is witnessing a surge in demand for bronchodilator drugs due to the high prevalence of respiratory diseases among its population.

Key regions: United States, Europe, Brazil, Japan, United Kingdom

Marché

Région

Comparaison de régions

Monnaie

Analyst Opinion

Bronchodilator drugs are widely used in France to treat respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD).

Customer preferences: In recent years, there has been a growing demand for bronchodilator drugs in France due to the increasing prevalence of respiratory diseases. Patients are increasingly seeking effective and long-lasting relief from their symptoms, leading to a rise in demand for combination bronchodilator therapies. Additionally, there is a trend towards the use of inhalers over traditional oral medications, as they are more convenient and have fewer side effects.

Trends in the market: One of the key trends in the bronchodilator drugs market in France is the increasing use of combination therapies. This is particularly true for patients with severe respiratory diseases who require more than one type of bronchodilator medication to manage their symptoms effectively. Combination therapies are also becoming more popular as they offer greater convenience and are often more cost-effective than using multiple medications separately.Another trend in the market is the growing use of biologic treatments for respiratory diseases. These drugs are designed to target specific pathways in the body that are involved in the development of respiratory diseases, offering a more targeted approach to treatment. While biologic treatments are currently relatively expensive, they are expected to become more widely used in the coming years as the cost of production decreases.

Local special circumstances: France has a well-developed healthcare system that provides universal coverage to all residents. This has helped to drive demand for bronchodilator drugs in the country, as patients are able to access the medications they need without facing significant financial barriers. Additionally, the French government has implemented a number of policies aimed at improving the management of respiratory diseases, including the development of national guidelines for the diagnosis and treatment of asthma and COPD.

Underlying macroeconomic factors: The French economy has experienced moderate growth in recent years, which has helped to drive demand for healthcare services. However, the country is facing a number of significant challenges, including an aging population and rising healthcare costs. This is likely to put pressure on the healthcare system in the coming years, which could impact the availability and affordability of bronchodilator drugs. Additionally, ongoing political and economic uncertainty in Europe could have an impact on the French economy and the healthcare sector more broadly.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.